Last update Jan. 16, 2021

Glimepiride

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Sulfonylurea that stimulates endogenous insulin secretion. May cause hypoglycemia.
Indicated in the treatment of type 2 diabetes.
Oral administration, one daily dose

We did not find published data regarding the excretion of this substance through breast milk at the time this last update was completed.

The manufacturer (AEMPS 2o18, Sanofi 2016) and some authors do not consider it safe in lactation based on a publication of excessive passage to milk in animals (Hale, Serrano 2015)

Until there is further published data on this drug in relation to breastfeeding, known safer alternatives may be preferable, especially during the neonatal period and in cases of prematurity.

Diet, exercise, and breastfeeding improve blood sugar levels.


See below the information of this related product:

  • Maternal Diabetes mellitus (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

  • Acarbose (Safe substance and/or breastfeeding is the best option.)
  • Ardeparin Sodium (Safe substance and/or breastfeeding is the best option.)
  • Glibenclamide (Safe substance and/or breastfeeding is the best option.)
  • Glipizide (Safe substance and/or breastfeeding is the best option.)
  • Hypocaloric Diet (Safe substance and/or breastfeeding is the best option.)
  • Insulin (Safe substance and/or breastfeeding is the best option.)
  • Metformin Hydrochloride (Safe substance and/or breastfeeding is the best option.)
  • Miglitol (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Glimepiride in other languages or writings:

Group

Glimepiride belongs to this group or family:

Tradenames

Main tradenames from several countries containing Glimepiride in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 490 daltons
Protein Binding 100 %
VD 0.12 l/Kg
pKa 4.32 -
Tmax 2 - 3 hours
T½ 5 - 9 hours

References

  1. AEMPS. Glimepirida. Ficha técnica. 2018 Full text (in our servers)
  2. Sanofi-Aventis. Glimepiride. Drug Summary. 2016 Full text (in our servers)
  3. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Jan 20;144(2):73-9. Abstract

Total visits

6,914

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM